We use essential cookies to make this site work.
We also use analytics cookies, by accepting you agree to their use.
You have accepted analytics cookies. You can change this choice at any time in settings.
You have rejected analytics cookies. You can change this choice at any time in settings.
STAY INFORMED! - If you are interested in receiving newsletters and updates, please send us your email to cksdrg@health.gov.sk
A List of requests and responses via feedback - CKS DRG
Thank You for your feedback. Your requests are being processed systematically according to the received date.
Current number of requests: 1024
Number of requests till 31.03.2026: 1006
Number of requests after 31.03.2026: 18
Handled suggestions: 690
Open suggestions: 35
Pending suggestions: 250
Suggestions downloaded by the submitter: 49
Dobrý deň, chcela by som Vás poprosiť o zaradenie výkonu 8r724.31 - zavedenie centrálneho venózneho katétra, PICC katétra s USG navigáciou medzi výkony, ktoré je možné vykonávať v režime JZS. Pacientom, ktorým je indikovaná chemoterapeutická liečba, je štandardom aplikácia PICC. Onkologickí pacienti majú problémy so zaistením periférneho intravenózneho vstupu a tí, ktorí sa podrobujú opakovaným podávaniam chemoterapie ambulantnou cestou (podávame aj v nemocniciach II.úrovne), sú traumatizovaní opakovaným zavádzaním týchto periférnych katétrov. Zavedenie PICC je metóda, ktorou sa šetrí periférny venózny vstup a zlepšuje benefit pre pacienta s dlhodobou chemoterapiou. Ďakujem
NsP Prievidza so sídlom v Bojniciach
Created at: 25.04.2025
One-day emergency room
Incentive to create
Kombinácia výkonov pri J0012
Fakultná nemocnica Trenčín
Created at: 22.04.2025
Coding rules and disputes
Dispute between ZP and PÚZS
Union ZP, a.s
Created at: 17.04.2025
Processed at: 07.04.2026
Attributable item
We have attributable items S01-01 Ranibizumab - Administration of Ranibizumab, intravitreal in the indication limitation and S01-02 Aflibercept - Administration of Aflibercept, intravitreal in the indication limitation in the KPP in the Medicines and Drug Products Annex. Other molecules categorised and used in practice - Brolucizumab, Faricimab and Dexamethasone - are administered, which will not be able to be reported as PPs and reimbursed or recorded as drug consumption in the transition to the DRG JHS.
Addition of the molecules in question to the PP Brolucizumab list - Administration of Brolucizumab, intravitreal in the indication restriction. Faricimab - Administration of Faricimab, intravitreal in the indication restriction. Dexamethasone - loc. intravitreal implant - Administration of Dexamethasone - intravitreal in the indication restriction. At the same time, move the above molecules, including Ranibizumab and Aflibercept, to Annex 7 of the PPJHS.
When switching to DRG JZS, it will not be possible to report the molecules in question as PP, reimburse and track consumption (reimbursement limit, MEA...).
That request was reconsidered and the Medical Review Panel proceeded to a vote, which is recorded in the minutes available here: https://www.cksdrg.sk/sk/dokumenty/571/Zápisy%20z%20rokovaní%20medicínsko-analytickej%20pracovnej%20skupiny%20s%20hlasovaniami.pdf
The proposed PPs have been approved and incorporated into the CMP with reimbursement type J.
Zaradenie lieku Talkvetamab do Katalógu prípadových paušálov ako pripočítateľnej položky s typom úhrady A
Fakultná nemocnica Nitra
Created at: 10.04.2025
Nemocnica Bory Pentahospitals
Created at: 08.04.2025
Requirement for PP medicine - tenecteplase
The opinion is set out in feedback number 659 - https://www.cksdrg.sk/sk/spatna-vazba/stanoviska/659
